APA (7th ed.) Citation

Eduardo Huarte, Michael T. Peel, Katherine Verbist, Brittany L. Fay, Rachel Bassett, Sabrin Albeituni, . . . Paul A. Smith. (2021). Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Eduardo Huarte, Michael T. Peel, Katherine Verbist, Brittany L. Fay, Rachel Bassett, Sabrin Albeituni, Kim E. Nichols, and Paul A. Smith. Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome. Frontiers Media S.A., 2021.

MLA (9th ed.) Citation

Eduardo Huarte, et al. Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome. Frontiers Media S.A., 2021.